Celldex Therapeutics (CLDX) Stock Price, News & Analysis

Company Overview

Celldex Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers. Other investigational compounds include varlilumab, an agonist antibody targeting CD27, CDX-301, a recombinant human Flt3 ligand designed to expand dendritic and immune cell populations, and CDX-1140, an antibody targeting CD40 to activate antigen-presenting cells. These programs are in various stages of clinical development, and Celldex collaborates with academic centers and industry partners to advance trials in the United States and select international sites.

Founded in 1997 and headquartered in Hampton, New Jersey, Celldex has evolved from a small discovery lab into a specialized immunotherapy company. Under the leadership of President and Chief Executive Officer Roger F. Dansey, M.D., the organization has strengthened its scientific expertise and manufacturing capabilities to support both early-stage and later-stage development activities. Celldex serves patients primarily in North America while maintaining strategic relationships to facilitate broader access to its investigational therapies in other regions.

Key Stats

• Today's Range: $21.77 to $23.69
• 50-Day Range: $20.01 to $25.50
• 52-Week Range: $14.40 to $47.00
• Volume: 1.60 million shs
• Average Volume: 1.01 million shs
• Market Capitalization: $1.57 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.67
• Consensus Rating: Moderate Buy

Celldex Therapeutics Stock Analysis - MarketRank™

Celldex Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 680th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Celldex Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Celldex Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Celldex Therapeutics are expected to decrease in the coming year, from ($2.48) to ($3.34) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Celldex Therapeutics is -7.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Celldex Therapeutics is -7.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Celldex Therapeutics has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.01% of the outstanding shares of Celldex Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Celldex Therapeutics has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Celldex Therapeutics has recently decreased by 6.04%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Celldex Therapeutics does not currently pay a dividend.

Dividend Growth

Celldex Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.01% of the outstanding shares of Celldex Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Celldex Therapeutics has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Celldex Therapeutics has recently decreased by 6.04%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.36

News Sentiment

Celldex Therapeutics has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Celldex Therapeutics this week, compared to 5 articles on an average week.

Search Interest

2 people have searched for CLDX on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Celldex Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Celldex Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.40% of the stock of Celldex Therapeutics is held by insiders.

CLDX Stock Analysis - Frequently Asked Questions

How have CLDX shares performed this year?

Celldex Therapeutics' stock was trading at $25.27 at the start of the year. Since then, CLDX shares have decreased by 7.7% and is now trading at $23.3250.

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its earnings results on Thursday, August, 7th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.86) by $0.01. The biopharmaceutical company earned $0.73 million during the quarter, compared to analysts' expectations of $1.13 million. Celldex Therapeutics had a negative trailing twelve-month return on equity of 27.61% and a negative net margin of 3,446.88%.

When did Celldex Therapeutics' stock split?

Celldex Therapeutics's stock reverse split before market open on Monday, February 11th 2019.The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' top institutional investors include Commodore Capital LP (5.20%), Bellevue Group AG (4.98%), Vestal Point Capital LP (2.64%) and Geode Capital Management LLC (2.52%). Insiders that own company stock include Anthony S Marucci, Samuel Bates Martin, Richard M Wright, Elizabeth Crowley, Margo Heath-Chiozzi and Diane C Young.
View institutional ownership trends.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Celldex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Celldex Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), Alphabet (GOOG) and Visa (V).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/03/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CLDX
• CIK: 744218
• Web: www.celldex.com
• Phone: (908) 454-7120
• Fax: 908-454-1911
• Employees: 150
• Year Founded: 1983

Price Target and Rating

• Average Price Target for Celldex Therapeutics: $46.67
• High Price Target: $67.00
• Low Price Target: $31.00
• Potential Upside/Downside: +100.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$157.86 million
• Net Margins: -3,446.88%
• Pretax Margin: -3,446.88%
• Return on Equity: -27.61%
• Return on Assets: -26.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.67
• Quick Ratio: 19.67

Sales & Book Value

• Annual Sales: $7.02 million
• Price / Sales: 220.66
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.87 per share
• Price / Book: 2.36

Miscellaneous

• Outstanding Shares: 66,410,000
• Free Float: 63,485,000
• Market Cap: $1.55 billion
• Optionable: Optionable
• Beta: 1.19